Synonym
Benzquinamide Free Base; HSDB3295; HSDB-3295; HSDB 3295; P2647; P-2647; P 2647
IUPAC/Chemical Name
2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-
InChi Key
JSZILQVIPPROJI-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3
SMILES Code
O=C(C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1OC(C)=O)N(CC)CC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
404.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Smith DJ, Rushin JM, Urquilla PR, Rhee CW, Yoon HJ, Simpson FA, Srichomkuan T, Lee HS, Knapp RB. Cardiovascular effects of benzquinamide. Anesth Analg. 1979 May-Jun;58(3):189-94. PMID: 582237.
2: Neidhart JA, Gagen M, Young D, Wilson HE. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Cancer. 1981 Mar 15;47(6):1439-43. doi: 10.1002/1097-0142(19810315)47:6<1439::aid- cncr2820470633>3.0.co;2-#. PMID: 7013968.
3: WISEMAN EH, SCHREIBER EC, PINSON R Jr. THE DISTRIBUTION, EXCRETION AND METABOLISM OF BENZQUINAMIDE. Biochem Pharmacol. 1964 Oct;13:1421-35. doi: 10.1016/0006-2952(64)90190-x. PMID: 14222190.
4: Steen SN, Yates M. The effects of benzquinamide and prochlorperazine, separately and combined, on the human respiratory center. Anesthesiology. 1972 May;36(5):519-20. doi: 10.1097/00000542-197205000-00025. PMID: 5067296.
5: Mull TD, Smith TC. Comparison of the ventilatory effects of two antiemetics, benzquinamide and prochlorperazine. Anesthesiology. 1974 Jun;40(6):581-7. doi: 10.1097/00000542-197406000-00013. PMID: 4406574.
6: Klein RL, Graves CL, Kim YI, Blatnick R. Inhibition of apomorphine-induced vomiting by benzquinamide. Clin Pharmacol Ther. 1970 Jul-Aug;11(4):530-7. doi: 10.1002/cpt1970114530. PMID: 4913868.
7: Hobbs DC, Connolly AG. Pharmacokinetics of benzquinamide in man. J Pharmacokinet Biopharm. 1978 Dec;6(6):477-85. doi: 10.1007/BF01062104. PMID: 581593.
8: Mazzanti R, Croop JM, Gatmaitan Z, Budding M, Steiglitz K, Arceci R, Arias IM. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65. PMID: 1362504.
9: Medoff J. A double-blind evaluation of the anti-emetic efficacy of benzquinamide, prochlorperazine and trimethobenzamide in office practice. Curr Ther Res Clin Exp. 1970 Nov;12(11):706-10. PMID: 4993123.
10: Carlsson A, Lindqvist M. The interference of tetrabenazine, benzquinamide and prenylamine with the action of reserpine. Acta Pharmacol Toxicol (Copenh). 1966;24(2):112-20. doi: 10.1111/j.1600-0773.1966.tb00374.x. PMID: 6013085.
